Literature DB >> 16622984

Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.

David Bushnell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16622984     DOI： 10.1016/j.gassur.2005.08.025

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  13 in total

1.  New advances in peptide receptor radionuclide therapy.

Authors:  Marion de Jong; Eric Krenning
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

2.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Authors:  Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

3.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

4.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Authors:  Raffaella Barone; Françoise Borson-Chazot; Roelf Valkema; Stéphan Walrand; Franck Chauvin; Lida Gogou; Larry K Kvols; Eric P Krenning; François Jamar; Stanislas Pauwels
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 5.  Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Authors:  Dik J Kwekkeboom; Jan Mueller-Brand; Giovanni Paganelli; Lowell B Anthony; Stanislas Pauwels; Larry K Kvols; Thomas M O'dorisio; Roelf Valkema; Lisa Bodei; Marco Chinol; Helmut R Maecke; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

6.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

7.  86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

Authors:  François Jamar; Raffaella Barone; Isabelle Mathieu; Stéphan Walrand; Daniel Labar; Pascal Carlier; Joëlle de Camps; Horst Schran; TianLing Chen; M Charles Smith; Hakim Bouterfa; Roelf Valkema; Eric P Krenning; Larry K Kvols; Stanislas Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-12       Impact factor: 9.236

8.  Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Authors:  Jaap J M Teunissen; Dik J Kwekkeboom; Eric P Krenning
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.

Authors:  David Bushnell; Yusuf Menda; Thomas O'Dorisio; Mark Madsen; Sara Miller; Thomas Carlisle; Shayne Squires; Daniel Kahn; Wayne Walkner; Mary Connolly; Sue O'Dorisio; Mark Karwal; James Ponto; Hakim Bouterfa
Journal:  Cancer Biother Radiopharm       Date:  2004-02       Impact factor: 3.099

Review 10.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.